Filing summary
Registrant clarification: The supplied filing is Jupiter Wellness, Inc.’s Form 10-Q, not a BONK, INC. filing. It covers the quarter and nine months ended September 30, 2022; financial statements are unaudited.
Business context and reporting period
Jupiter Wellness develops topical wellness and therapeutic products, including CBD-based candidates, and sells theme-park merchandise through SRM Entertainment. Management describes a shift toward scientifically supported OTC and prescription products, licensing, and contract research services. SRM generated nearly all reported revenue in the first nine months of 2022.
Key financial metrics
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Revenue | $1.570 million | $0.688 million | $5.291 million | $1.332 million |
| Gross profit | $0.413 million | $0.002 million | $1.036 million | $0.209 million |
| Gross margin | 26.3% | 0.3% | 19.6% | 15.7% |
| Net loss | $2.332 million | $4.808 million | $6.693 million | $11.155 million |
| Basic loss per share | $0.10 | $0.24 | $0.30 | $0.79 |
At September 30, 2022, cash was $3.565 million; current assets were $8.401 million and current liabilities $2.964 million. Total assets were $12.086 million, total liabilities $3.529 million, and shareholders’ equity $8.557 million. Current liabilities included $1.892 million of convertible notes, net of discounts. The notes had $2.0 million principal outstanding and were extended to April 20, 2023; they bear 8% interest and are convertible at $2.79 per share, with warrants issued alongside them. The company also reported $47,981 outstanding on an SBA EIDL loan and $719,985 of lease liabilities.
For the first nine months, operating cash use was $4.750 million, investing cash use was $2.492 million, and financing cash use was $0.946 million. Cash declined by $8.189 million from $11.755 million at year-end 2021. The filing reports no cash paid for interest or income taxes in the period.
Material changes versus prior comparable period
- Revenue rose 128% in Q3 and 297% for the first nine months year over year. Management attributed the increase to recovery in demand after pandemic-related weakness; segment data show SRM contributed $5.200 million of nine-month 2022 sales.
- Gross margin improved substantially in Q3 and increased for the nine-month period, although the company remained loss-making.
- Nine-month net loss narrowed by about 40%, with lower general and administrative and stock-based compensation costs than in 2021. The comparison also reflects a $664,095 net gain in 2021, principally from settlement-related debt forgiveness, versus a $1.0 million promissory-note impairment charge in 2022.
- Cash fell by $8.189 million, including $2.880 million used to repurchase shares. The company repurchased 2,825,617 shares at an average cost of about $1.02 per share; 391,723 repurchased shares remained in treasury at quarter-end.
Outlook, commentary, risks, and unusual items
- No quantified revenue, earnings, or cash-flow guidance is provided. Management describes continued development and licensing of product candidates, including JW-100 for eczema, and says it aims to expand its contract research business in 2023. The filing describes clinical and regulatory plans as forward-looking, not guaranteed outcomes.
- The company paid $1.5 million under a clinical research agreement with an approximate $3.0 million budget; the remaining prepaid balance was $1.288 million at quarter-end.
- A $2.908 million investment in JWAC-related founder shares and private-placement units is recorded as a current affiliate promissory-note asset and accounted for as held to maturity. Its liquidity and recovery terms merit review.
- The company reported an unresolved federal lawsuit involving the Koch Parties, including a remaining unjust-enrichment counterclaim against Jupiter and its CEO. A jury trial was rescheduled to March 27, 2023. The company’s complaint seeks $5 million in actual and $5 million in punitive damages; those amounts are claims, not recognized assets.
- In 2022, the company recorded a $1.0 million impairment related to the NFP note after NFP terminated the acquisition agreement. The filing also describes a $10.0 million impairment charged to 2021 earnings. Nasdaq listing-rule issues concerning equity awards were addressed through cancellations and share reallocations; the company says it regained compliance.
- Management concluded disclosure controls were effective at September 30, 2022 and described remediation of previously disclosed internal-control weaknesses, including adding experienced personnel and improving and testing financial controls. The company is an emerging growth company and smaller reporting company.
Important facts for investors to verify
- Confirm the correct issuer: the supplied document identifies Jupiter Wellness, Inc. (JUPW/JUPWW), not BONK, INC.
- Reconcile the Q3 net loss: the financial statements report $2,332,426, while one MD&A table gives $2,232,426; the financial statements also report $2,332,426.
- Assess the recoverability, classification, and liquidity of the $2.908 million affiliate investment and the terms and remaining obligations of the NFP note impairment.
- Review cash burn, remaining research-agreement commitments, convertible-note maturity and conversion/dilution terms, and the substantial outstanding warrant and option overhang.
- Track the unresolved litigation, clinical and regulatory milestones, and execution of management’s stated licensing and contract-research plans.